Skin imaging study in eczema patients receiving nemolizumab
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have moderate-to-severe atopic dermatitis (eczema) that your doctor recommends treating with nemolizumab.
- You are willing to try nemolizumab and follow the study procedures.
- You do not have an uncontrolled chronic disease (like diabetes or asthma) that needs steroids.
- You do not have another serious illness that would make it unsafe to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (SIM0278) given as an injection to see if it helps reduce eczema symptoms. It is for people with moderate to severe atopic dermatitis who have not used certain other treatments recently.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
This study tests a new injectable medicine (nemolizumab) for people with moderate-to-severe eczema that hasn't been helped enough by topical treatments. It aims to reduce itching and skin symptoms. The trial will compare the drug to a placebo in Chinese participants.
This study uses special imaging to look at the structure of skin, comparing people with eczema (who have used steroid creams) to healthy volunteers. Researchers want to understand how the skin changes with eczema and its treatment.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
Hear when a new Atopic Dermatitis (Eczema) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.